Abstract
New recommendations for HER2 status (receptor or gene) testing in breast cancer were published following long-term analysis of clinical effectiveness of molecularly targeted treatment based on predictive factor of HER2 status. The new protocols were developed to eliminate equivocal cases, and the new procedure leads to final statement as HER2 positive or HER2 negative. Current testing algorythms are presented.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
